Isaac Ciechanover, new Qiming partner
June 3, 2022 07:22 AM EDT
Financing

All in on ear­ly-stage, Qim­ing US bags $260M, re­cruits Atara founder Isaac Ciechanover for Fund III

Amber Tong

Senior Editor

Even as some of the pub­lic biotech com­pa­nies in its port­fo­lio bend un­der the weight of a bear mar­ket, Qim­ing Ven­ture Part­ners USA is rolling up its sleeves to build more star­tups.

The VC firm has tak­en the wraps off a $260 mil­lion third fund, dubbed US Health­care Fund III, to ex­e­cute on the same strat­e­gy as pre­vi­ous funds: in­vest in ear­ly-stage ther­a­peu­tics and health­care tech­nol­o­gy com­pa­nies in the US and the EU.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

TRENDING NOW

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

Bit­ter­root Bio nabs $145M Se­ries A with a plan to tack­le chal­leng­ing can­cer tar­get for heart med­i­cines

Up­dat­ed: FDA sig­nals like­ly full ap­proval for Ei­sai's new Alzheimer's drug ahead of Fri­day's ad­comm

Fi­bro­Gen grap­ples with PhI­II set­back in Duchenne mus­cu­lar dy­s­tro­phy

LNP biotech looks to go be­yond the liv­er, rais­ing $25M in seed mon­ey to move for­ward

sponsored

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

A service from the Financial Times